Evidence map›Paper›PMID 38712312›Full record

ArticleRespiratory medicine case reports2024

Pembrolizumab-induced asthma exacerbation with hypereosinophilia and elevated interleukin-5 in endometrial cancer: A case report.

Tomoya Harada, Naoki Uetani, Genki Inui, Hiroki Ishikawa, Yoshihiro Funaki, Miki Takata, Ryota Okazaki, Kosuke Yamaguchi, Masato Morita, Shin Kitatani and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tomoya HaradaDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Naoki UetaniDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Genki InuiDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Hiroki IshikawaDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Yoshihiro FunakiDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Miki TakataDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Ryota OkazakiDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Kosuke YamaguchiDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Masato MoritaDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.
Shin KitataniDepartment of Respirology, Tottori Prefectural Kousei Hospital, Tottori, Japan.
Akira YamasakiDivision of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University, Tottori, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pembrolizumab is an anti-programmed cell death-1 (PD-1) antibody used to treat various cancer types. Treatments with such immune checkpoint inhibitors cause immune-related adverse events. However, airway inflammation caused by immune-related adverse events has rarely been reported. A 54-year-old woman with endometrial cancer experienced asthma exacerbation, and increased blood eosinophil counts 3 months after pembrolizumab administration. Although asthma exacerbation improved, the resumption of pembrolizumab caused the recurrence of dry cough and hypereosinophilia. The discontinuation of pembrolizumab improved her symptoms. Serum interleukin-5 levels increased during pembrolizumab treatment but decreased upon discontinuation. The blockade of PD-1 and its ligand may exacerbate asthma through eosinophilic inflammation.

Indexed as

AsthmaEosinophilImmune checkpoint inhibitorImmune-related adverse eventsPembrolizumab

Identifiers

PMID38712312
PMCPMC11070912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.